在一般人群中预测新发慢性肝病模型(CLivD评分)的开发与验证
基于芬兰FINRISK 1992-2012和Health 2000队列25760名40-70岁人群开发CLivD评分,含年龄、性别、饮酒量、腰臀比、糖尿病、吸烟,有无谷氨酰转移酶两个版本,在Whitehall II和CCHS队列外部验证,15年AUC为0.65-0.78。
要点
- CLivD评分基于年龄、性别、饮酒量、腰臀比、糖尿病、吸烟等常见因素。
- 含实验室指标的Modellab内部验证C-statistic为0.77,不含实验室指标的Modelnon-lab为0.75。
- 模型可识别绝对15年肝脏事件风险>10%的小部分人群(<2%)。
核心结论
- 基于广泛可得的危险因素,CLivD评分可用于预测一般人群未来发生严重肝病的风险。
研究设计与样本
- 多变量Cox回归分析用于开发肝脏结局预测模型,在芬兰基于人群的健康检查调查FINRISK 1992-2012和Health 2000(推导队列)的25760名40-70岁个体中进行,模型分含实验室指标(Modellab)和不含实验室指标(Modelnon-lab)两个版本。
- 模型在Whitehall II(n=5058)和Copenhagen City Heart Study(CCHS)(n=3049)队列中进行外部验证。
主要发现
- 新发肝脏结局的绝对发生率范围为每10万人年53至144。
- 最终预测模型包括年龄、性别、饮酒量(杯/周)、腰臀比、糖尿病和吸烟,Modellab还包括谷氨酰转移酶值。
- 内部验证Wolbers C-statistic为Modellab 0.77、Modelnon-lab 0.75,表观15年AUC分别为0.84(95% CI 0.75-0.93)和0.82(95% CI 0.74-0.91)。
- 模型识别出小部分人群(<2%)具有>10%的绝对15年肝脏事件风险。
- 所有肝脏事件中仅10%发生在最低风险类别参与者中。
临床怎么用
- CLivD评分可作为健康咨询的一部分,并用于规划进一步的肝脏检查和随访。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Current screening strategies for chronic liver disease focus on detection of subclinical advanced liver fibrosis but cannot identify those at high future risk of severe liver disease. Our aim was to develop and validate a risk prediction model for incident chronic liver disease in the general population based on widely available factors. METHODS: Multivariable Cox regression analyses were used to develop prediction models for liver-related outcomes with and without laboratory measures (Modellab and Modelnon-lab) in 25,760 individuals aged 40-70 years. Their data were sourced from the Finnish population-based health examination surveys FINRISK 1992-2012 and Health 2000 (derivation cohort). The models were externally validated in the Whitehall II (n = 5,058) and Copenhagen City Heart Study (CCHS) (n = 3,049) cohorts. RESULTS: The absolute rate of incident liver outcomes per 100,000 person-years ranged from 53 to 144. The final prediction model included age, sex, alcohol use (drinks/week), waist-hip ratio, diabetes, and smoking, and Modellab also included gamma-glutamyltransferase values. Internally validated Wolbers' C-statistics were 0.77 for Modellab and 0.75 for Modelnon-lab, while apparent 15-year AUCs were 0.84 (95% CI 0.75-0.93) and 0.82 (95% CI 0.74-0.91). The models identified a small proportion (<2%) of the population with >10% absolute 15-year risk for liver events. Of all liver events, only 10% occurred in participants in the lowest risk category. In the validation cohorts, 15-year AUCs were 0.78 (Modellab) and 0.65 (Modelnon-lab) in the CCHS cohort, and 0.78 (Modelnon-lab) in the Whitehall II cohort. CONCLUSIONS: Based on widely available risk factors, the Chronic Liver Disease (CLivD) score can be used to predict risk of future advanced liver disease in the general population. LAY SUMMARY: Liver disease often progresses silently without symptoms and thus the diagnosis is often delayed until severe complications occur and prognosis becomes poor. In order to identify individuals in the general population who have a high risk of developing severe liver disease in the future, we developed and validated a Chronic Liver Disease (CLivD) risk prediction score, based on age, sex, alcohol use, waist-hip ratio, diabetes, and smoking, with or without measurement of the liver enzyme gamma-glutamyltransferase. The CLivD score can be used as part of health counseling, and for planning further liver investigations and follow-up.
引用
- Åberg F, Luukkonen PK, But A, et al. Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score. J Hepatol. 2022. PMID: 35271949. doi:10.1016/j.jhep.2022.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。